FUJIFILM Biotechnologies, a prominent contract development and manufacturing organization (CDMO), is currently navigating a period of unprecedented expansion, marked by…
Read More
Calderasib’s Real Innovation: Designed for Combinability and Potency Unlocks New Frontiers in KRAS-Mutated Cancers
Merck’s latest investigational drug, calderasib, is not merely another entry into the burgeoning field of KRAS G12C inhibition; it represents…
Read More
Retatrutide eases sleep apnea and knee arthritis in new Phase 3 data, extending Lilly’s obesity lead over Novo
Eli Lilly and Company has announced groundbreaking Phase 3 results for its investigational triple agonist, retatrutide, demonstrating significant efficacy in…
Read More
CEO of CDMO AustinPx on its exclusive agreement with Thermo Fisher’s Patheon division
AustinPx, a Contract Development and Manufacturing Organization (CDMO) based in Texas, has forged an exclusive agreement with Thermo Fisher Scientific’s…
Read More
Remepy’s Hybridopa, a Pioneer in AI-Driven Hybrid Drugs, Demonstrates Significant Efficacy in Parkinson’s Phase IIa Trial
San Francisco, CA – May 2026 – Remepy, a burgeoning health technology startup at the vanguard of integrating pharmaceutical and…
Read More
As cell therapies scale and CDMOs cut staff, process know-how is often getting lost in tech transfer
The pharmaceutical industry, particularly the rapidly evolving biopharmaceutical sector, faces a silent but significant challenge: the erosion of critical "tacit…
Read More
What if psilocybin works about as well for depression as an SSRI?
The burgeoning optimism surrounding classic psychedelics as revolutionary treatments for depression may need a recalibration, as emerging data suggests their…
Read More
Lilly offers up to $3.8 billion for AtaiBeckley in bet on ‘God molecule’ found in toad venom
Eli Lilly has formally agreed to acquire AtaiBeckley for a substantial sum, comprising $2.8 billion upfront and an additional $1…
Read More
Diabetes to MASH: the specimens behind GLP-1’s widening roster
The therapeutic landscape for metabolic diseases has been irrevocably reshaped by the emergence of GLP-1 receptor agonists, a class of…
Read More
How ConcertAI turned CancerLinQ into a point-of-care oncology intelligence platform
Over a decade ago, the American Society of Clinical Oncology (ASCO) initiated a groundbreaking endeavor with the launch of CancerLinQ,…
Read More
